Why diversity in clinical trials is essential to the future of UK life sciences
Date: 26 April 2023
Becoming a world leader in equality, diversity and inclusion (EDI) is essential if the UK life sciences sector wants to set itself apart from its competitors – particularly in the area of clinical trials. That is the finding of a new report from MedCity, the Faculty of Pharmaceutical Medicine and Imperial College Healthcare NHS Trust.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok